Solutions

MEDGADGET                                                                                   Aug. 20, 2015

BOSTON --At the 250^th National Meeting & Exposition of the American Chemical Society this week, researchers from MIT, Harvard Med School, and the FDA are showing off a new field test that can quickly screen people for Ebola, yellow fever, and dengue. While the researchers don’t claim their technique to be as accurate as PCR and ELISA, it is nevertheless an excellent tool in poor areas of the world where these diseases tend to thrive.

The test doesn’t require any water or electricity nor any complicated and expensive equipment. It works similar to pregnancy tests, providing a color readout that signals whether a disease is detected that is easily readable by just about anyone.

The Completed Containerized Biocontainment Systems Units at Dobbins Air Force Base, in Marietta, Georgia

blogs.state.gov - by Andrew O'Brien - August 13, 2015

In treating Ebola internationally, U.S. government personnel, doctors, nurses, aid workers, and other global health professionals are often put in direct contact with Ebola, and unfortunately some contract the virus themselves. Yet with limited resources, the U.S. Department of State needed more capacity to safely transport these Ebola patients to treatment facilities. Additionally, availability of medevac is important to getting doctors and epidemiologists from all over the world to volunteer to join the Ebola response.

By partnering with the Paul G. Allen Family Fund we were able to confront this challenge head on. Two containerized medevac biocontainment systems were funded by a $5 million grant by the Paul G. Allen Family Fund and the units were unveiled on August 11th at an event recognizing the partnership. MRIGlobal, a leading research institute, built the units, which are fully equipped to transport four patients, contain a broader array of dangerous pathogens, and fly aboard both military and civilian aircraft to multiple destinations in a single mission.

The most promising soil and water management practices will be scaled up. Photo: N. Palmer (CIAT)

ccafs.cgiar.org - by Mathieu Ouedraogo, Sibiri Jean Ouedraogo, Sekou Toure, Maimouna Fane - August 11, 2015

A collaboration among regional research institutes and National Agricultural Research Systems establishes strong partnership for upscaling the “farms of the future” approach.

In West Africa, climate change brings new challenges to agriculture. Among other things, it is straining the livelihoods of the rural population, given their high dependence on the climate.

Because these challenges cannot be addressed by one research institution alone, the CGIAR Research Program on Climate Change, Agriculture and Food Security (CCAFS) tackles the problem through an intervention approach based on a worldwide strategic collaboration between CGIAR and Future Earth.

PHARMACEUTICAL PROCESSING by  Princeton University, Woodrow Wilson School of Public and International Affairs   Aug. 6, 2015

Ebola is a preventable disease, and yet a safe and effective vaccine has not been deployed. As with many vaccines, financial barriers persist: pharmaceutical companies see high costs with limited market potential, and government support is lacking. But there may be a solution to this vaccine crisis with the ability to save at-risk populations, according to a perspective piece written by physicians based at Princeton University, University of Pennsylvania and the Wellcome Trust.

The article, published in the New England Journal of Medicine, proposes the creation of a $2 billion global vaccine-development fund - supported by governments, foundations and pharmaceutical companies - that would carry promising vaccines through development to deployment. With initial support, the global vaccine fund could help make vaccines available for emergency use.